Gilead

Page 2 of 4

COVID forgotten communities
Newsletters

The communities we forget during COVID-19

By
April 30, 2020
Gilead remdesivir coronavirus FDA
Health

Gilead’s remdesivir won’t be a COVID-19 miracle cure, but it’s still an important first step

By
April 30, 2020
Gilead says COVID-19 recovery drug hit primary target
Health

Gilead says COVID-19 recovery drug hit primary target

By
April 29, 2020
Gilead coronavirus drug effective in coronavirus patients: report
Health

Gilead stock surges on report of coronavirus drug patients ‘seeing rapid recoveries’

By Drew Armstrong and Bloomberg
April 16, 2020
Gilead coronavirus
Newsletters

Gilead made a remarkable request of the FDA in regard to its coronavirus drug

By
March 25, 2020
Coronavirus drug Gilead Washington
Health

Gilead’s coronavirus treatment is already being used in Washington state

By
March 10, 2020
Gilead coronavirus trial
Newsletters

Can Gilead tame the coronavirus?

By
February 27, 2020
Gilead remdesivir clinical trials
Health

Gilead’s coronavirus treatment is barreling its way into new clinical trials

By
February 27, 2020
COVID-19-Coronavirus-microscope
Health

The first U.S. trial for a coronavirus treatment has started

By
February 25, 2020
Coronavirus vaccine development
Health

The first coronavirus drug candidate is set for testing in China

By
February 3, 2020
Biotech IPO Allogene
Health

Why Cancer Biotech Allogene Just Scored an Eye Popping $324 Million IPO

By
October 11, 2018
The American Enterprise Institute photo of Scott Gottlieb
Health

The FDA Is Naming and Shaming Companies Accused of Blocking Cheap Generic Drugs

By
May 17, 2018
Hepatitis C drug can cure, if patients can get it
Health

Hepatitis C Drugs Can Cost $84,000. This New One May Be Just As Good—But Cost $300

By
April 12, 2018
A picture taken on May 11, 2012 in a pha
Health

New Zealand Is About to Make the Revolutionary HIV Prevention Drug Truvada Almost Free

By
February 7, 2018
Inside The Nasdaq MarketSite As Juno Therapeutics Releases IPO
Health

Why Analysts Are Calling Celgene’s $9 Billion Juno Acquisition a ‘Smart’ Biotech Deal

By
January 22, 2018

Most Popular